Treatment of insulin resistance

Garth Cooper (Other), Howard Greene Jr (Inventor)

    Research output: Patent


    Compounds and methods for blocking the effects of diabetes-associated peptide, or "amylin", a hormone found in the amyloid masses of Type 2 diabetics. This putative hormone has been discovered to function both to inhibit insulin secretion and to inhibit glycogen synthesis. Regulation is accomplished by blocking the binding of amylin or amylin agonists, including calcitonin gene related peptide (CGRP], or biologically active sub-peptides thereof. Inhibitors include substituted peptides or sub-peptides of amylin or CGRP, cross-linked amylin and amylin agonists, synthetic amylin, anti-amylin receptor antibodies and anti-idiotype antibodies, and antibodies directed to amylin and amylin agonist active sites. Other antagonists include organic compounds which can be screened and assayed for anti-amylin effects by disclosed methods.
    Original languageEnglish
    Patent number5,281,581
    Publication statusPublished - 25 Jan 1994


    Dive into the research topics of 'Treatment of insulin resistance'. Together they form a unique fingerprint.

    Cite this